✔️ Watch again the complete SAC-FAC Session in the SOLACI-CACI 2021 Congress. 👨🏫 Program: – SESSION I: Functional Mitral Regurgitation: New Horizons for Transcatheter Therapy 01:06 – Optimal Medical Treatment in Patients with Cardiac Failure and Mitral Regurgitation – Florencia Renedo 12:12 – Ultrasonographic Screening of Patients for Endovascular Therapy – Walter García 25:43 –…
Can Ticagrelor Prevent Strokes in High-Risk Patients?
In addition to aspirin, Ticagrelor offers better prognosis in patients that already had a stroke and have a high-risk cardiovascular profile. These benefits should be correctly balanced seeing as they are not free of risk. Antiplatelet therapy makes part of the standard treatment of cardiac or cerebrovascular patients. Ticagrelor has shown superior to clopidogrel in…
ESC 2021 | ENVISAGE-TAVI AF: Surprise with Endoxaban in TAVR and Atrial Fibrillation
The enthusiasm for direct oral anticoagulants after transcatheter aortic valve replacements (TAVR) is waning. At least, when it combines with atrial fibrillation. The ENVISAGE-TAVI AF has shown excessive bleeding with endoxaban vs. the classical vitamin K antagonists. Endoxaban resulted non-inferior to vitamin K antagonists in terms of net clinical adverse events, but major bleeding events…
HOST-EXAM: The Study that Challenges Aspirin as Long-Term Antiplatelet Therapy
The HOST-EXAM study (which was prospective, randomized, and open-label, with the participation of 37 Korean sites) was specifically designed to determine the role of aspirin as the long-term antiplatelet therapy of choice after angioplasty with current drug-eluting stents. To this end, the study compared aspirin head-to-head with clopidogrel. Over the course of four years, 5438 patients (mean…
ESC 2021 | STEP: Blood Pressure Values in the Elderly, A Never-Ending Debate
The results of the STEP study were presented at the European Society of Cardiology (ESC) 2021 Congress! The main finding from this research was that an ideal target of 110 mmHg or at least <130 mmHg blood pressure (compared with a target of 130 mmHg or at least 150 mmHg) yielded an absolute risk reduction of composite events of…
ESC 2021 | GREENNESS: Surprising New Protective Factor against Cardiovascular Disease
What Is “Greenness”? This factor—which generally refers to the proximity to vegetation, as measured by satellite pictures—could serve as a new protection against cardiovascular disease. During five years (the total research time), this study compared individuals who lived in the lowest tercile of “greenness” with those who lived in the highest tercile (i.e., those who…
ESC 2021 | Empagliflozin in Heart Failure with Reduced and Preserved Ejection Fraction
The full results of the EMPEROR-Preserved study confirm as findings that empagliflozin decreases the risk of death or hospitalization for heart failure (HF) in both patients with reduced and with preserved function. The primary endpoint (a composite of death and hospitalization for HF) was reduced by 21% on a relative basis with sodium/glucose cotransporter 2…
ESC 2021 | ISAR-REACT 5: Prasugrel Superior to Ticagrelor in ACS across Kidney Function Spectrum
When we have to choose between two potent P2Y12 receptor inhibitors for a patient undergoing ACS with a planned invasive strategy, kidney function should not interfere in this decision. The main findings of this study were that prasugrel has lower risk of all cause death, MI or stroke, and also had a similar risk of…
ESC 2021 | MASTER DAPT: Dual Antiplatelet Therapy After Coronary Angioplasty in Patients at High Bleeding Risk
Courtesy of Dr. José Álvarez. In patients at high bleeding risk with drug-eluting stents, the duration of dual antiplatelet therapy has been subjected to ongoing review. Guidelines from the European Society of Cardiology (ESC) and the American College of Cardiology (ACC) suggest shortening this treatment to a maximum of three to six months (Class IIb).…
Dual Antiaggregation De-Escalation: A New Paradigm?
De-escalating dual antiaggregation could be the most effective strategy after acute coronary syndrome seeing as it prevents bleeding and cut down costs with no increase of ischemic events. Balancing the effects of dual antiaggregation therapy (DAPT) in the era of potent P2Y12 inhibitors has become the cornerstone of acute coronary syndrome (ACS) management. This meta-analysis…
The Role of Aspirin after the TWILIGHT-ACS
This analysis corroborates the potential benefit of ticagrelor monotherapy following a short period of dual antiaggregation (DAPT) in patients with acute coronary syndrome (ACS). This benefit consists of a significant bleeding reduction (3.6% vs. 7.6%, P < 0.001), without compromising ischemic events (4.3% vs. 4.4%, P = 0.84). The latter, however, could be seen as…